Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus.
The antiviral activity of a novel biological response modifier (murabutide MDP derivative) has been investigated in 3-week-old OF1 mice infected with influenza (A/Texas/1/77) virus. In each experimental and control group, 10 mice were infected intranasally with a viral dose producing 50% mortality in 5 days and received murabutide via the subcutaneous or intranasal route at various doses either in a simple or in daily repeated administration. All experiments were done in triplicate. Significant prophylactic or therapeutic effects were observed when murabutide was administered the same day as virus, 4 days or 2 days before virus, and 2 days later. These effects varied with the route of administration and the doses of the compound.
Chomel
J J
JJ
Laboratoire de Virologie, Université C. Bernard Lyon I, France.
Simon-Lavoine
N
N
Thouvenot
D
D
Valette
M
M
Choay
J
J
Chedid
L
L
Aymard
M
M
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000281:Administration, Intranasal; D000818:Animals; D004305:Dose-Response Relationship, Drug; D053122:Influenza A Virus, H3N2 Subtype; D009980:Influenza A virus; D007279:Injections, Subcutaneous; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*
D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033575:murabutide